Fibrin clot method

A fibrin clot containing adsorbed plasmin inhibitors is difficult to define in a chemical or physical sense. Generally, when enzyme reactions occur at surfaces, the porosities and adsorption properties erf which are variable, the reproducibility of enzyme assay methods is questionable. The proteinoses, to which belong the most important pharmaceutical enzymes, may present some difficulties when natural substrates (protein ) are prescribed. Here, the application of a parallel run with a reference standard is recommended. 

A new approach to thrombosis therapy using acyl plasmins has been reported by Smith et al.78). Acyl plasmin is catalytically inert and unable to react with plasma inhibitors but still can bind to a fibrin clot. Thus, after the administration, acyl plasmin can circulate without being trapped by the inhibitors and can come into contact with fibrin. Deacylation may then occur to give a fibrin-plasmin complex and this active enzyme is expected to lead to fibrinolysis. The preparation of acyl plasmin of appropriate stability was realized by using the general procedure for the specific synthesis of an acyl enzyme — the inverse substrate method. 

False negative results for cTn may occur if the assay is insufficiently sensitive, especially in enzyme-linked immunosorbent assay (ELISA) methods where colorimetry rather than fluorescence or chemiluminescence is used as the detection method, and in those assays with poor cross-species reactivity. False negative results may also occur in samples that have deteriorated. Serum cTn is stable at -70°C, but it deteriorates several percent per day at 4°C and by 10% per week at -20°C. Rare false positive results may occur with circulating heterophilic antibodies, fibrin clots, or incomplete serum separation (or in the presence of rheumatoid factor). Hemolysis produces negligible interference. 

Fibrin clots in plasma from overfilling interference of tube additive in test method hemolysis fiom underfilfing Assay interference hemolysate contains biomarker or releases intracellular proteases that degrade the biomarker Assay interference... 

Fibrin does not exist as such in the blood, and the method of its formation and of the clotting of blood has been the subject of much experiment and argument nor can the question be said to be definitely set at rest. In the light of the researches of Denis, Schmidt, and especially of Hammarsten, it may be considered as almost proven that fibrin is formed from fibrinogen under favorable circumstances, and by a transformation which is not yet understood. Whether paraglobulin plays any part directly in the formation of fibrin or not, is still an open question. 

---